Published in Cancer Cell on December 01, 2006
Modes of p53 regulation. Cell (2009) 9.31
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
Two faces of p53: aging and tumor suppression. Nucleic Acids Res (2007) 2.78
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer (2011) 2.06
Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res (2008) 2.04
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
The multiple levels of regulation by p53 ubiquitination. Cell Death Differ (2010) 1.87
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
The impact of acetylation and deacetylation on the p53 pathway. Protein Cell (2011) 1.66
p53-based cancer therapy. Cold Spring Harb Perspect Biol (2010) 1.62
MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
p53 regulation by ubiquitin. FEBS Lett (2011) 1.51
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ (2013) 1.50
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell (2012) 1.40
Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev (2007) 1.37
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Recent advances in p53 research and cancer treatment. J Biomed Biotechnol (2011) 1.31
The p53 circuit board. Biochim Biophys Acta (2012) 1.24
Mouse models of p53 functions. Cold Spring Harb Perspect Biol (2009) 1.23
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell (2010) 1.21
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ (2008) 1.17
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev (2013) 1.11
Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev (2011) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol (2011) 1.08
IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation. EMBO J (2010) 1.08
Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol (2011) 1.05
Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem (2007) 1.03
How cell death shapes cancer. Cell Death Dis (2015) 1.01
p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia (2012) 1.01
MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res (2012) 1.00
Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice. J Biol Chem (2011) 1.00
TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated phosphorylation and autodegradation during DNA damage. Mol Cell Biol (2014) 1.00
Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet (2011) 0.99
NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. J Cell Biol (2015) 0.99
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget (2011) 0.98
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol (2012) 0.97
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. Genes Cancer (2011) 0.96
Crosstalk between p53 and TGF-β Signalling. J Signal Transduct (2012) 0.95
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
Mdm2 is required for maintenance of the nephrogenic niche. Dev Biol (2014) 0.92
Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther (2008) 0.92
E2 ligase dRad6 regulates DMP53 turnover in Drosophila. J Biol Chem (2011) 0.90
Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev (2008) 0.90
Mouse models of Mdm2 and Mdm4 and their clinical implications. Chin J Cancer (2013) 0.89
Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol (2014) 0.87
Mdm2 and MdmX as Regulators of Gene Expression. Genes Cancer (2012) 0.87
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharm Biomed Anal (2009) 0.86
Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther (2010) 0.85
Ubiquitylation of p53 by the APC/C inhibitor Trim39. Proc Natl Acad Sci U S A (2012) 0.85
Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction. J Biol Chem (2012) 0.84
cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle (2012) 0.84
It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53. Genes Cancer (2012) 0.83
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A (2013) 0.82
Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. PLoS One (2012) 0.81
New targets for the treatment of follicular lymphoma. J Hematol Oncol (2009) 0.80
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. Oncotarget (2016) 0.80
Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget (2014) 0.79
Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One (2013) 0.79
p53 E3 ubiquitin protein ligase homolog regulates p53 in vivo in the adult mouse eye lens. Mol Vis (2013) 0.78
Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas. Oncogene (2017) 0.77
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. J Cancer (2016) 0.77
MDM2 oligomers: antagonizers of the guardian of the genome. Oncogene (2016) 0.76
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. Oncoscience (2014) 0.76
Accumulation of p53 via down-regulation of UBE2D family genes is a critical pathway for cadmium-induced renal toxicity. Sci Rep (2016) 0.76
p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res (2015) 0.76
Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Mol Cancer Ther (2016) 0.75
Ubiquitin-specific peptidase 48 regulates Mdm2 protein levels independent of its deubiquitinase activity. Sci Rep (2017) 0.75
MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury. Cell Death Dis (2016) 0.75
Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors. J Cancer (2016) 0.75
Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development. Sci Rep (2017) 0.75
Targeting MDM4 Splicing in Cancers. Genes (Basel) (2017) 0.75
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumorigenesis. J Pathol (2016) 0.75
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch (2017) 0.75
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell (2002) 5.29
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
A matter of life and death. Cancer Cell (2002) 4.07
Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med (2007) 3.11
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature (2010) 2.51
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
Temporal dissection of p53 function in vitro and in vivo. Nat Genet (2005) 2.19
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Heterochromatin silencing of p53 target genes by a small viral protein. Nature (2010) 2.12
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev (2006) 1.87
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2011) 1.84
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
The ups and downs of Myc biology. Curr Opin Genet Dev (2009) 1.70
Aberrant 3' oligoadenylation of spliceosomal U6 small nuclear RNA in poikiloderma with neutropenia. Blood (2012) 1.68
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell (2013) 1.68
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res (2006) 1.64
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev (2013) 1.60
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res (2004) 1.48
c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol (2002) 1.43
Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res (2006) 1.42
Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene (2004) 1.32
The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell (2002) 1.24
A structural basis for the assembly and functions of a viral polymer that inactivates multiple tumor suppressors. Cell (2012) 1.23
Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol (2009) 1.21
A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife (2013) 1.20
Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov (2013) 1.17
Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J Biol Chem (2006) 1.16
The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. J Gen Virol (2004) 1.14
Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell (2006) 1.11
Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem (2004) 1.11
Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev (2011) 1.11
The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One (2011) 1.10
Recovery High Schools: A Descriptive Study of School Programs and Students. J Groups Addict Recover (2008) 1.08
The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res (2008) 1.02
The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res (2004) 0.98
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther (2007) 0.96
Finding cancer's weakest link. Oncotarget (2011) 0.96
Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. Neoplasia (2011) 0.92
Critical role for arginine methylation in adenovirus-infected cells. J Virol (2007) 0.90
Id2 is dispensable for Myc-induced epidermal neoplasia. Mol Cell Biol (2004) 0.90
Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest (2013) 0.90
PTEN deletion and concomitant c-Myc activation do not lead to tumor formation in pancreatic beta cells. J Biol Chem (2008) 0.89
The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication. Wiley Interdiscip Rev Syst Biol Med (2010) 0.88
KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo. Cell Cycle (2014) 0.87
All things to all people. Cell (2012) 0.85
Nursing some sense out of Myc. J Biol (2009) 0.85
Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation. J Biol Chem (2009) 0.83
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A (2013) 0.82
aMAGEing new players enter the RING to promote ubiquitylation. Mol Cell (2010) 0.81
Molecular mechanisms of neuronal cell death: implications for nuclear factors responding to cAMP and phorbol esters. Mol Cell Neurosci (2002) 0.75